

Supplementary Table 4. Clinical characteristics of human lung adenocarcinoma samples

Sample	Timepoint	% tumor cells	Response	Duration of Response (Months)	TKI Status at Repeat Biopsy (Time off Erlotinib)
Y1	Initial Diagnosis	50			
	Erlotinib Resistance	40	Yes	4.1 M	On
Y2	Initial Diagnosis	60			
	Erlotinib Resist. (2nd time)	60	Yes	5.5 M	On ¹
Y3	Initial Diagnosis	50			
	Erlotinib Resistance	60	N/A ²	36.8 M	Off (14 M)
Y4	Initial Diagnosis	70			
	Erlotinib Resistance	75	Yes	6.1 M	On
Y5	Pre Erlotinib	75			
	Erlotinib Resistance	50	Yes ³	4.4M	On
Y6	Pre-Erlotinib	30			
	Erlotinib Resistance	75	Yes	8.3M	On
Y7	Pre Erlotinib	40			
	Erlotinib Resistance	40	Yes	7.8M	On
Y8	Pre Erlotinib	80			
	Erlotinib Resistance	70	Yes	10.1M	On
Y9	Initial Diagnosis	60			
	Erlotinib Resistance	80	Yes	8.4M	Off (3.4M) ⁴
Y10	Initial Diagnosis	80			
	Erlotinib Resistance	80	Yes	27.2M	Off (1D)

¹ Off Erlotinib for 4.7 M, reintroduced w/ Pemetrexed for 4.1 M before repeat biopsy

² Received Erlotinib adjuvantly

³ Previously received Erlotinib adjuvantly

⁴ Off Erlotinib for 13M, rechallenged 4x, 4M, then off for 3.4M